Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer
- 26 Downloads
The aim of this study was to investigate the efficacy and safety profiles of cetuximab, the commonly used monoclonal antibody of epidermal growth factor receptor, based on Chinese patients with colorectal cancer.
All the papers studied on Chinese patients with gastrointestinal cancer treated by cetuximab and found in both databases of Chinese journal database for fulltext and PubMed were collected. The commonly used efficacy index such as disease control rate (CR + PR + SD) and response rate (CR + PR) were analyzed, and the cetuximab related side effects such acne-like rash and nail change and hypersensitivity were analyzed too.
(1) There were 10 original papers contained total 152 patients with gastrointestinal cancer who were the candidates to analyze the safety profiles, and contained 130 patients with colorectal cancer who were candidates to analyze the efficacy. (2) The disease control rate and response rate in the whole group was 73.5% (95% CI: 65.5%–81.5%) and 29.1% (95% CI: 20.9%–37.3%), respectively; In first-line setting group they were 70.0% (95% CI: 55%–85%) and 41.7% (95% CI: 25.6%–57.8%), respectively; In non-first line setting group they were 71.6% (95% CI: 61.8%–81.4%) and 23.5% (95% CI: 14.3%–32.7%), respectively. The disease control rate between the two line-setting groups was insignificant, but the response rate between the two line-setting groups was significant (P = 0.045). (3) The incidence of acne-like rash was 72.0% (95% CI: 64.8%–79.2%), the degree I–II and degree III–IV account for 56.0% (95% CI: 48.1%–63.9%) and 16.0% (95% CI: 10.1%–21.9%), respectively. No treatment related death, and the hypersensitivity was under control.
This study is the first study to summarize the data of Chinese patients with colorectal cancer treated by cetuximab-contained regimen, it showed that the monoclonal antibody was effective and safe for Chinese patients as the West patients with colorectal cancer.
Key wordsChinese patient colorectal cancer cetuximab efficacy side effects
Unable to display preview. Download preview PDF.
- 6.Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol, 2007, 25: 5777–5784.PubMedCrossRefGoogle Scholar
- 8.Zhang WF, Liu LK, Liu YQ. Clinical usefulness of cetuximab in combination with chemotherapy in the treatment of gastrointestinal cancer. Chin J Mod Drug Appl (Chinese), 2008, 12: 18–20.Google Scholar
- 9.Ye HY, Zhang YH, Chen JQ, et al. Effects of cetuximab plus chemotherapy in first-line treatment of advanced colorectal cancer. Chin Oncol (Chinese), 2008, 18: 704–706.Google Scholar
- 10.Jin X, Bai Y, Yu JL, et al. The clinical observation of cetuximab in combination with chemotherapy in metastatic colorectal cancer patients. J Basic Clin Oncol (Chinese), 2008, 21: 682–882.Google Scholar
- 11.Zhang XT, Shen L, Zhang XD, et al. Cetuximab in combinationn with chemotherapy for patients with gastrointestinal cancer. Chin J Oncol (Chinese), 2008, 30: 385–388.Google Scholar
- 12.Wang M, Wang W, Li YM, et al. Cetuximab plus mIFL in treatment of oxaliplatin-resistant metastatic colorectal cancer: efficacy and toxicity. Chin J Cancer Biother (Chinese), 2008, 15: 371–571.Google Scholar
- 13.Lin RB, Guo ZQ, Chen YG, et al. Cetuximab in combination with irinotecan to treat chemotherapy-resistant advanced colorectal cancer. Chin Oncol (Chinese), 2008, 18: 79–80.Google Scholar
- 14.Qian J, Qin SK, Cao MR, et al. The clinical observation of cetuximab plus irinotecan in the treatment of refractory metastatic colorectal cancer. Chin Oncol (Chinese), 2007, 17: 92–94.Google Scholar
- 15.Huang JZ, Dong MX, Yu SK. Clinical observation of combination chemotherapy for metastatic colorectal cancer with Cetuximab. Chin Pract Med (Chinese), 2007, 2: 9–11.Google Scholar
- 16.Wang RZ, Chen ZQ, Wu PE, et al. Cetuximab plus chemotherapy and/or radiotherapy in the treatment of refractory metastatic cancer. Chin Oncol (Chinese), 2007, 17: 653–656.Google Scholar
- 17.Hu WM, Deng XF, Lu WQ, et al. Clinical observation of cetuximab plus irinotecan in the treatment of advanced colorectal cancer. J Pract Med (Chinese), 2007, 23: 2591–2592.Google Scholar
- 21.Haller DJ, Cassidy J, Clarke S, et al. Tolerability of fluoropyrimidines appears to differ by region. J Clin Oncol, 2006, 24(June 20 Suppl): 3514.Google Scholar